SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is currently experiencing intense market volatility as investors weigh strong earnings and a massive record backlog against concerns over a significant new capital raise and heavy AI infrastructure spending. While the community remains divided, with many citing the dilution as a short-term pressure point, bullish investors are highlighting the company's surging demand and long-term positioning as a critical player in the AI buildout.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is facing significant selling pressure as investors react to a $7 billion capital raise intended to fund a substantial backlog of AI server orders. The community remains deeply polarized, with some bulls viewing the dilution as a necessary step for hyper-growth and capacity expansion, while bears cite recurring concerns over corporate governance, accounting transparency, and the potential for further share price volatility.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is experiencing intense market volatility as community discourse centers on escalating geopolitical tensions in the Middle East and concerns over persistent inflation. Investors and critics alike are actively debating the company's financial future amidst broader market instability and controversial executive commentary regarding the current economic climate.

SpaceX

SpaceX is generating massive market buzz ahead of its highly anticipated IPO, with the offering reportedly oversubscribed as investors rotate capital from tech and semiconductor holdings to secure a position. The community is sharply divided, with some investors betting on the company's long-term dominance in space infrastructure and AI computing, while others remain skeptical of the valuation and warn that retail traders are being positioned as exit liquidity for early institutional backers.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently at the center of investor focus as the market gears up for the historic SpaceX IPO, with community sentiment split between those viewing the event as a catalyst for sector-wide valuation re-ratings and others bracing for short-term volatility or rotation. Discussions are heavily centered on the potential for institutional capital flows to benefit high-quality public space pure-plays like RKLB, even as traders debate technical support levels amid broader market macro pressure.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnson is currently in the spotlight due to a mix of positive sentiment surrounding its oncology pipeline, specifically the recent FDA approval of Icotyde, and persistent legal headwinds from ongoing talc-related litigation. The community is actively debating the company's long-term growth potential and M&A activity as it shifts focus toward innovative medicine and medtech while navigating massive, high-profile legal liabilities.

GE Vernova, Inc. engages in the electric power industry. It operates through the following segments: Power, Wind, and Electrification. The Power segment offers design, manufacture, and servicing gas, nuclear, hydro, and steam technologies, providing a critical foundation of dispatchable, flexible, stable, and reliable power. The Wind segment manages wind generation technologies, including onshore and offshore wind turbines and blades. The Electrification segment refers to the grid solutions, power conversion, electrification software, and solar and storage solutions technologies required for the transmission, distribution, conversion, storage, and orchestration of electricity from point of generation to point of consumption. The company was founded November 9, 2021 and is headquartered in Cambridge, MA.

GE Vernova Inc.

GE Vernova is trending as investors weigh the stock's significant backlog in grid infrastructure against recent volatility and technical corrections. The community remains divided between those viewing the pullback as a buying opportunity given the long-term energy demand from AI data centers, and others expressing concern over potential institutional profit-taking and technical setups.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is rallying behind its transition toward an energy infrastructure business, specifically targeting the data center market through new battery storage solutions. Investors are actively debating whether this pivot warrants a sustained rerating to higher price levels or if the stock's recent momentum is merely a short-term pump driven by speculative options activity.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It operates through the following segments: Uranium, Rare Earth Elements (REE), and Heavy Mineral Sands (HMS). The uranium segment engages in conventional and ISR uranium extraction, recovery and sales of uranium from mineral properties and the recycling of uranium-bearing materials generated by third parties along with the exploration, permitting and evaluation of uranium properties in the U.S. The REE segment is engaged in the company’s initiatives to progress towards full REE separation capabilities at the Mill to produce both light and heavy separated REE oxides in the coming years. The HMS segment engages in the exploration, development and recovery of HMS at the Kwale Project, Bahia Project, Vara Mada Project and the company’s equity method investments in the Donald Project JV and Tate. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels is trending as investors monitor ongoing institutional interest and institutional-grade financing alongside the company's strategic position in the domestic uranium and rare earth supply chain. While some community members remain frustrated by recent volatility and price pullbacks, active discussions highlight the critical role of these materials in supporting AI data center power needs and the broader U.S. energy transition.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is facing significant backlash from investors who are calling for the resignation of CEO Irwin Simon, citing persistent share dilution and the stock's poor performance as primary concerns. While the company is actively expanding its beverage portfolio and pursuing medical cannabis opportunities, the community remains deeply divided by skepticism regarding management's strategic focus and a perceived lack of clear progress in the U.S. market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LIXTE Biotechnology Holdings (NASDAQ: LIXT) Unlocking New Potential in Precision Cancer Treatment

LIXTE Biotechnology Holdings (NASDAQ: LIXT)&#160;is advancing the precision oncology landscape, developing therapies that complement existing cancer treatments while integrating cutting-edge data solutions. “The company’s lead program, LB-100, is a novel small-molecule compound designed to enhance the efficacy of chemotherapy and radiation, aiming to improve patient outcomes while reducing treatment-related side effects,” reads a recent article. [&#8230;]

LIXTE Biotechnology Holdings (NASDAQ: LIXT) Positions LB-100 as Novel Approach in Cancer Treatment Landscape

Boca Raton, Florida-based&#160;LIXTE Biotechnology Holdings (NASDAQ: LIXT)&#160;spent 2025 expanding its presence across multiple segments of oncology innovation. “The company is best known for its clinical-stage pharmaceutical pipeline built around LB-100, a first-in-class inhibitor of protein phosphatase 2A (‘PP2A’),” a recent article reads. “Rather than replacing established cancer therapies, LB-100 is designed to enhance their effectiveness. [&#8230;]

LIXTE Biotechnology (NASDAQ: LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference

LIXTE Biotechnology Holdings (NASDAQ: LIXT),&#160;a clinical-stage pharmaceutical company advancing cancer treatments, announced preliminary results from a clinical trial evaluating its proprietary compound LB-100 in combination with&#160;dostarlimab&#160;at the 2026 Society of Gynecologic Oncology conference in San Juan, Puerto Rico. Interim data from 20 evaluable patients showed a 40% disease control rate and encouraging survival trends with [&#8230;]

Lixte Biotech Holdings (NASDAQ: LIXT) Advances Precision Oncology Strategy with LB-100, Expands Clinical and Strategic Partnerships

Lixte Biotechnology (NASDAQ: LIXT)&#160;is emerging as a differentiated player in the oncology ecosystem, advancing a precision-driven approach to cancer treatment which focuses on improving the effectiveness of existing. As a clinical-stage pharmaceutical company, the company is advancing novel compounds built around a unique biological target, with its lead candidate, LB-100, at the nucleus of its [&#8230;]

LIXTE Biotechnology (NASDAQ: LIXT) Has the World’s Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is in the unique position of holding the world’s only clinical-stage protein phosphatase 2A (“PP2A”) inhibitor, called LB-100. The LB-100 compound is a proprietary small-molecule PP2A inhibitor that is designed to target protein phosphatase 2A (“PP2A”), introducing a potential new treatment paradigm aimed at enhancing existing&#8230; [&#8230;]

LIXTE Biotechnology (NASDAQ: LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials

Ovarian clear cell carcinoma and metastatic colon cancer remain among the most challenging malignancies to treat, with limited effective therapies and poor patient outcomes driving the urgent need for new approaches. LIXTE Biotechnology Holdings (NASDAQ: LIXT) is dedicated to addressing that need through the continued development of its lead compound LB-100. Recent updates from the company highlight expanding clinical [&#8230;]

Lixte Biotech (NASDAQ: LIXT) Advances Precision Oncology with LB-100, Strengthens Position Through Liora Technologies Partnership

Lixte Biotech Holdings (NASDAQ: LIXT)&#160;is advancing the frontiers of precision oncology, developing therapies that complement existing cancer treatments while integrating cutting-edge data solutions. The company’s lead program, LB-100, is a novel small-molecule compound designed to enhance the efficacy of chemotherapy and radiation, aiming to improve patient outcomes while reducing treatment-related side effects. By focusing on [&#8230;]

Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing a drug class called protein phosphatase 2A inhibitors. The firm is also involved in utilizing biomarker technology to identify enzyme targets associated with serious common diseases and then designing novel compounds to attack those targets. The company was founded by John S. Kovach and Robert B. Royds on May 24, 2005 and is headquartered in Boca Raton, FL.

Current Price	$6.89
Prev Close	$6.87
Open	$6.85
Dividend Yield	0.00%
50-Day Moving Average	$4.61
Beta	0.66
Avg. Volume	105,009.21
PE Ratio	-6.13

52-Week High	$7.50
52-Week Low	$0.64
Market Capitalization	$119.44M
EPS (Annual)	-$1.26
Price to Book	10.09
Revenue Per Employee	$0.00

LIXTLixte Biotechnology Holdings Inc

Fundamentals

Feed

News

Sentiment

Fundamentals

Info

Latest LIXT News